People who live in areas that have higher exposure to nitrogen dioxide were found to be at greater risk of Parkinson disease.
Residing in areas with busy roads or highways that are prone to greater exposure of nitrogen dioxide (NO2) may increase risk of Parkinson disease (PD), according to study findings published in JAMA Neurology.
Researchers highlight that air pollution exposure, a significant public health hazard, affects more than 80% of urban area residents at levels exceeding that set by the World Health Organization.
Associated with several adverse events, including migraine prevalence and severity, and increased risk of death from respiratory disease, researchers say that long-term air pollution exposure has been identified to be associated with neurodegenerative diseases through systemic inflammation, oxidative stress, and direct invasion into the brain.
Moreover, they note that exposures to environmental pollutants, such as pesticides, metals, and air pollution, have been suggested as risk factors for PD.
Seeking to further assess this potential link, particularly which air pollutants may increase risk of PD development, researchers examined retrospective data from the Korean National Health Insurance Service for individual exposure levels to particulate matters (PM2.5 and PM10), NO2, ozone (O3), sulfur dioxide (SO2), and carbon monoxide (CO).
“Since most studies were conducted in North American and European countries, there is a need for investigation in Asian countries, where air pollutant levels are generally higher than those in other countries,” noted researchers.
The study included 78,830 adults older than 40 years without PD (mean [SD] age, 54.4 [10.7] years; 52.1% female) who lived in Seoul, South Korea, between January 2002 and December 2006, and met inclusion criteria. The study cohort participated in annual follow-ups from January 2007 to December 2015, amounting to 757,704 total person-years of follow-up.
Each participant’s exposure level to the air pollutants was estimated by residential address at the district level, in which a time-varying 5-year mean air pollutant exposure was calculated to evaluate long-term impact.
Among the study cohort, 338 participants were newly diagnosed with PD in the 9 years of follow-up, in which those who developed incident PD were significantly older (mean [SD] age, 54.4 [10.7] years vs 66.5 [9.7] years; P < .001) and were more likely to be receiving Medicaid (2.8% [2208 of 78,830] vs 7.1% [24 of 338]; P < .001).
In assessing the air pollutants, NO2 was the sole pollutant whose exposure was associated with risk of incident PD (HR for highest vs lowest quartile, 1.41; 95% CI, 1.02-1.95; P = .045 for trend), which remained robust after adjusting for confounders, such as age, sex, and insurance type.
“This finding suggests the role of air pollutants in PD development, advocating for the need to implement a targeted public health policy,” said the study authors. “To account for the long prodromal stage of PD, the effect of air pollutants according to various exposure duration and lag analysis should be investigated.”
Reference
Jo S, Kim YJ, Park KW, et al. Association of NO2 and other air pollution exposures with the risk of Parkinson disease. JAMA Neurol. Published online May 17, 2021. doi:10.1001/jamaneurol.2021.1335
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
Certain Patient Groups Continue to Be Underrepresented in PD Studies in the Netherlands
February 4th 2023With greater attention being paid to the heterogenous patient population, researchers questioned whether this has resulted in a more diverse group of patients included in Parkinson disease (PD) studies in the Netherlands.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen
Motor Symptoms May Occur 3 Years Before Parkinson Disease Diagnosis, Study Says
January 20th 2023Trouble with balance and holding objects above one's head were just a few of the problems reported by patients 3 years before they received a formal Parkinson disease diagnosis, according to a recent study.
Read More